crispin uro 400 mg tabletti, kalvopäällysteinen
grünenthal gmbh - gatifloxacini sesquihydricum - tabletti, kalvopäällysteinen - 400 mg - gatifloksasiini
alea comp 20 mg / 5 mg / 12.5 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - olmesartani medoxomilas,amlodipini besilas,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 20 mg / 5 mg / 12.5 mg - olmesartaanimedoksomiili, amlodipiini ja hydroklooritiatsidi
alea comp 40 mg / 5 mg / 12.5 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - hydrochlorothiazidum,olmesartani medoxomilas,amlodipini besilas - tabletti, kalvopäällysteinen - 40 mg / 5 mg / 12.5 mg - olmesartaanimedoksomiili, amlodipiini ja hydroklooritiatsidi
alea comp 40 mg / 10 mg / 12.5 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - olmesartani medoxomilas,hydrochlorothiazidum,amlodipini besilas - tabletti, kalvopäällysteinen - 40 mg / 10 mg / 12.5 mg - olmesartaanimedoksomiili, amlodipiini ja hydroklooritiatsidi
alea comp 40 mg / 5 mg / 25 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - amlodipini besilas,hydrochlorothiazidum,olmesartani medoxomilas - tabletti, kalvopäällysteinen - 40 mg / 5 mg / 25 mg - olmesartaanimedoksomiili, amlodipiini ja hydroklooritiatsidi
alea comp 40 mg / 10 mg / 25 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - hydrochlorothiazidum,olmesartani medoxomilas,amlodipini besilas - tabletti, kalvopäällysteinen - 40 mg / 10 mg / 25 mg - olmesartaanimedoksomiili, amlodipiini ja hydroklooritiatsidi
posaconazole stada 100 mg enterotabletti
stada arzneimittel ag - posaconazole - enterotabletti - 100 mg - posakonatsoli
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubisiinihydrokloridia - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiset aineet - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).